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Populations Using Zona Pellucida lmmunogens 
Bonnie S. Dunbar 
Introduction 
The human population presently exceeds 6 billion and 
is continuing to expand at a startling rate. This 
population increase has resulted in the depletion of 
Earth's resources, which are essential for human 
survival. An unfortunate consequence of this expan- 
sion has been the destruction of wildlife habitats. As 
these habitats have diminished, numerous problems 
have arisen. includina conflicts between wildlife and 
- 
human populations. The threat of extinction of many 
plant and animal species has already become a 
reality; other wildlife populations have increased due 
to reductions in predator populations. While the 
increase in the human population must ultimately be 
checked, there is a need for effective and humane 
methods to regulate certain animal populations as 
well. Another factor relevant to animal overpopulation 
is regional distribution. Widespread overpopulation of 
such animals as white-tailed deer in North America 
and rabbits in Australia has caused environmental as 
well as health problems for humans. In Asia and 
Africa, the populations of some wildlife species, such 
as elephants, have been dramatically reduced. Often 
these animals have frequently been relegated to small 
areas of land that do not have sufficient resources to 
sustain them. There is a vicinal distribution of elephants 
in Asia and Africa whose localized high populations 
threaten the destruction of their own restricted habitats. 
The rising domestic pet population also contin- 
ues to be a problem, as more than 27 million dogs and 
cats are impounded annually in the United States, with 
more than 17 million of them being euthanized (Carter 
1990). The extent of domestic pet overpopulation 
poses ethical as well as health-related dilemmas 
(Flowers 1979, Carter 1990). Countless dollars are 
spent each year to house and dispose of impounded 
animals and to combat diseases transmitted by the 
fleas and ticks that use the dogs and cats as hosts. 
As these problems continue to intensify, it is apparent 
that a serious need exists for effective and inexpen- 
sive methods of population control. 
Conventional Methods of Animal 
Population Control 
Despite the need for effective animal population 
control, few methods are available which are practical 
or cost effective for large-scale administration. The 
major methods of current methods are summarized 
below. 
Surgical Sterilization 
Of the surgical sterilization methods recommended for 
dogs and cats, the surgical removal of the uterus and 
cervix (where possible) as well as the ovary (ovario- 
hysterectomy) has several advantages over partial 
removal of reproductive organs. 
While neutering of male animals by castration is 
also common, this procedure may not ultimately have 
a dramatic impact on population reduction in many 
animal populations where one virile male can mate 
with numerous females. It is also apparent that 
surgical procedures are not practical for large-scale 
sterilization of major populations of mammalian 
wildlife. 
Endocrine Regulation of Fertility 
Numerous steroid treatments have been tested for 
their ability to regulate fertility in animals, including 
treatment with progestogens or androgens. In female 
dogs, these hormones have been shown to suppress 
normal ovarian cyclicity. Many of the treatment 
regimens that include progestins have been found to 
promote the development of cystic endometrial 
hyperplasia and subsequent uterine infection, mam- 
mary development, and posttherapy lactation, while 
androgens may induce external masculinization. 
Alternatively, endocrine administration for the inhibition 
of implantation is possible. Because these methods 
have adverse effects in some animal species and 
because they are expensive and require regular 
administration, these methods are not generally 
considered to be practical for regulation of large 
populations of wildlife; for these reasons, they will not 
be dealt with in more detail. 
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Contraceptive Vaccines for Animal 
Fertility Regulation 
The theory that immunization could be used as a 
method of contraception has led to numerous investi- 
gations into the development of safe and effective 
contraceptive vaccines. These vaccines have pro- 
posed the use of a variety of antigens as targets that 
would be specific for hormones, gametes, or other 
reproductive tissues. These vaccines use a variety of 
antigens as targets which would be specific for 
hormones, gametes, or other reproductive tissues 
(see reviews by Alexander et al. [I9901 and Dunbar 
and O'Rand [ I  9921). This brief overview is not intended 
to provide a detailed outline of all research in this 
area. 
The development of contraceptive vaccines is 
distinct from that of vaccines to control infectious 
diseases. Therefore, many of the approaches used in 
this area are unique. First, the contraceptive vaccines 
will be administered to normal, healthy individuals and 
not to infected or ailing individuals. Second, most 
traditional vaccines are directed against foreign 
organisms such as viruses or bacteria; contraceptive 
vaccines must elicit an immune response against 
"self" molecules that would not normally be recognized 
as foreign. This means that the "self" molecule to be 
used in the vaccine must be presented to the body in 
a "foreign" or "nonself" form in order for the immune 
system to respond effectively. These unique features 
have provided a significant challenge to investigators 
in the field as described in more detail below. 
A second major factor relating to the develop- 
ment of contraceptive vaccines is that the immune 
system interacts with the male gonads in a different 
way than it does with the female system. It is well 
established that there is a blood-testis barrier in the 
male that partially protects the developing sperm in 
the testis from the immune system. The developing 
spermatozoa are formed at a stage long after the 
immune system has developed the capability to 
distinguish self from nonself antigens. Because 
ovaries initiate oocytes before birth in the human and 
many other animal species, the same immunological 
barriers are not developed. These fundamental 
differences have required that vaccines targeted 
toward the male be developed in a different manner 
than those for the female. 
Although the ideal vaccine has yet to be formu- 
lated, research has provided a great deal of informa- 
tion relating to the fundamental mechanisms of 
hormone action, gamete interaction, fertilization, and 
implantation. These detailed studies have been 
important not only in laying the foundation for future 
development of contraceptive methods but also in 
developing a better understanding of reproductive 
systems of many mammalian species. 
While the development of a contraceptive 
vaccine for humans has the criteria that it must be 
safe, effective, and potentially reversible, the criteria 
for wildlife management are different. In some animal 
populations, it is desired (if not required) that animals 
be permanently sterilized. In other populations, such 
as some captive animals in zoo or farms, it is desir- 
able that the vaccine be reversible. This is an essen- 
tial requirement where it is important not to deplete a 
potential gene pool even though there is temporary 
abundance of a species or where there is a temporary 
lack of space for housing animals. It is likely, there- 
fore, that several strategies will be necessary to 
develop optimal vaccines for different animal species. 
Hormone-Based Contraceptive 
Vaccines 
To date, many of the more applied studies have been 
carried out using peptide hormones as immunogens. 
These include the peptide hormones, human chorionic 
gonadotrophin (hCG), luteinizing hormone (LH), follicle- 
stimulating hormone (FSH), and the gonadotropin- 
releasing hormones (see review by Stevens [I9881 
and articles by Thau et al. [I9871 and Mougdal 
[1990]). Of these potential vaccines, the most exten- 
sive studies conducted to date have been on the hCG 
(see reviews by Gupta and Koothan [I9901 and Griffin 
[1991a,b]). The hCG vaccine, which is most ad- 
vanced in clinical studies for human contraception, is 
limited to efficacy in primates and is not applicable to 
the majority of wildlife species. Because it interrupts 
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pregnancy rather than preventing it, this vaccine may 
not be a universally accepted alternative to contracep- 
tion. Although some of these vaccines have promise 
for human contraception, their modes of action make 
them less likely to be effective for large-scale animal 
populations. 
Gamete-Based Contraceptive 
Vaccines 
Sperm Antigens 
The onset of spermatogenesis and the appearance of 
mature sperm in the male reproductive tract occur 
during puberty at a time well beyond the establishment 
of immunological competence and tolerance to 
autoantigens (see review by Simon and Alexander 
[1988]). The further development of the male gamete 
occurs elsewhere in that it must mature in the epididy- 
mis (Dacheux et al. 1990, Cameo et al. 1990) and 
pass through the male reproductive tract, during which 
time the sperm surface antigens are modified (Isojima 
and Koyama 1988). Finally, the sperm are further 
modified in the female reproductive tract, where sperm 
capacitation occurs (Yanagimachi 1989, Bedford 
1991). It is therefore possible to interfere with sperm 
function at several points in the reproductive process. 
Because antibodies are produced against 
spermatozoa, Rosenfeld (1 926) suggested that 
women repeatedly injected with human semen would 
become infertile. Since these early investigations, 
numerous studies by many laboratories have concen- 
trated on identifying sperm antigens that would be 
(1) specific for sperm and not cross-react with any 
other cell types so they would not elicit antibodies with 
deleterious side effects on other tissues, and (2) present 
on the sperm surface or involved in the fertilization 
process so that antibodies would be able to inhibit 
fertility. These studies have been reviewed in detail 
elsewhere (O'Rand and Fisher 1988, Simon and 
Alexander 1988). Again, although these vaccines hold 
great promise for human vaccine development, they 
may not be practical for large-scale animal populations 
unless temporary infertility is desired and continuous 
and long-term antibodies can be sustained. 
Oocyte and Zona Pellucida (ZP) 
Antigens 
Studies on the identification of oocyte-specific anti- 
gens have been less numerous than those of sperm 
antigens for the simple reason that large numbers of 
mammalian eggs are not readily available to carry out 
many of the biochemical studies necessary for such 
research. The development of procedures to isolate 
large numbers of oocytes with their surrounding egg 
coat, the zona pellucida (ZP), has made it possible to 
study the study the glycoprotein antigens of the ZP in 
great detail (see review by Timmons and Dunbar 
[ I  9881). 
The antigens of the ZP have long been consid- 
ered to be an attractive target for immunological 
contraceptive or sterilization vaccines for several 
reasons. For human contraceptive vaccines, antibodies 
directed against the ZP antigens expressed at later 
stages of oocyte development should inhibit fertiliza- 
tion (i.e., this would be a nonabortive method). Alter- 
natively, if antibodies are directed against ZP antigens 
expressed early in oocyte growth and follicular devel- 
opment, permanent sterilization may result because all 
oocytes are ultimately destroyed and no steroids will 
be produced. This latter method would be preferable 
for use in animal sterilization. 
Because there are a limited number of glycopro- 
teins associated with the ZP, the major proteins of 
several species have been studied in great detail. To 
date, three major glycoproteins have been identified in 
most species (see review by Timmons and Dunbar 
[1988]). Many studies have demonstrated that both 
the immunogenicity and antigenicity of the ZP glyco- 
proteins is extremely complex (see discussion below 
on general aspects of immunogenicity and antigenicity). 
Antibodies can be identified which recognize amino 
acid and carbohydrate epitopes as well as conforma- 
tional or structural epitopes of the ZP (Maresh and 
Dunbar 1987). Further, it is not possible to predict the 
immune response of a given animal when immunized 
with ZP antigens of a different species. Because 
isoimmunization with the ZP glycoproteins of the same 
species does not elicit a significant response, it has 
become apparent that immunogenicity of ZP is primarily 
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due to the foreign epitopes associated with the ZP of 
different species. These observations have further 
been demonstrated by the necessity to conjugate the 
A mouse peptide to the foreign molecule, keyhole 
limpet hemocyanin, to elicit an immune response. The 
distinct species differences in the antigens of ZP of 
different mammalian species and the need to define 
antigenic epitopes which will elicit antibodies that 
prevent fertilization but do not alter ovarian function 
foster the necessity to dissect the antigenic domains 
of the ZP glycoproteins. 
Studies have also demonstrated that immuniza- 
tion with some ZP antigens can elicit an immune 
response which interferes with development of ovarian 
follicles (Skinner et al. 1984, Dunbar et al. 1989, Rhim 
et al. 1992, and Lee and Dunbar 1992). These effects 
vary among different mammals and may mimic such 
clinical conditions as premature ovarian failure, and 
polycystic ovarian disease. In the development of 
animal sterilization vaccines, it is preferable to eliminate 
growing oocytes along with the hormone-secreting 
granulosa and theca cells, which are responsible for 
estrous behavior. These side effects are not accept- 
able for the development of a human contraceptive 
vaccine. 
In view of these observations and the need to 
develop different vaccines which may cause tempo- 
rary or permanent infertility, it has been necessary to 
study the formation and development of the ZP during 
ovarian follicular development. These studies have 
demonstrated that the ZP proteins are produced in 
follicle stage-specific sequence (Wolgemuth et al. 
1984, Lee and Dunbar 1992) and that the distinct ZP 
antigens are synthesized and secreted at different 
stages of development. It should therefore be pos- 
sible to identify distinct antigenic epitopes that are 
associated with the ZP matrix following the differentia- 
tion of the steroid-producing granulosa cells. 
Molecular biology techniques have allowed for 
the further study of ZP proteins' antigenic domains. 
Initial studies of molecular cloning and characteriza- 
tion of complimentary deoxyribonucleic acids (cDNA's) 
encoding the ZP glycoproteins of mouse and rabbit 
have been described (Ringuette et al. 1986, Liang et 
al. 1990, and Schwoebel et al. 1991). These studies 
have demonstrated the rabbit ZP 55 Kd antigen has a 
distinct amino acid sequence (Schwoebel et al. 1991) 
from the two sequences of mouse ZP proteins 
(Ringuette et al. 1986, Liang et al. 1990). Further- 
more, the 55 Kd protein does not appear to be present 
in the mouse genome. A rabbit 75 Kd ZP protein has 
demonstrated significant similarity (70 percent) with 
the amino acid sequence of the mouse ZP2 protein, 
and cDNA isolated against the 55 Kd rabbit ZP protein 
has demonstrated that the pig has a homologue of this 
rabbit protein. 
The complete amino acid sequences of ZP 
proteins for several species will ultimately be needed 
to determine their species similarities and determine 
vaccine efficacy. Results of these studies could 
explain why immunization of mice or rats with the ZP 
of pig ZP antigens does not cause infertility (Drell et al. 
1984, Sacco et al. 1981), while immunization of other 
mammalian species including nonhuman primates 
with pig ZP proteins effectively reduces fertility (Drell 
et al. 1984, Skinner et al. 1984 and 1989, Dunbar et 
al. 1989). 
Recently, studies have been carried out using 
the expression of ZP proteins produced using recom- 
binant DNA techniques to begin to define specific 
epitopes that may be effectively used to develop a 
contraceptive vaccine. This vaccine would inhibit 
fertilization but not affect the early stages of ovarian 
follicular development (Schwoebel et al. 1991). These 
studies are the first to demonstrate that ZP proteins 
produced using bacterially expressed recombinant 
DNA techniques can elicit in monkeys antibodies that 
recognize the native ZP antigen. Furthermore, 
cynomolgus monkeys immunized with 55 Kd rabbit ZP 
protein show no alteration of ovarian follicular devel- 
opment, but antibodies to this protein inhibit monkey 
sperm from binding to monkey ZP. This is in contrast 
to monkeys immunized with a portion of the rabbit 
75 Kd rabbit ZP protein, which does alter ovarian 
follicular development. Thus, antigenic domains of ZP 
proteins can also be dissected to define which ZP 
proteins will elicit specific antibodies that either 
( I )  inhibit sperm binding to the ZP without affecting 
ovarian follicular development or (2) reduce the 
number of ovarian follicles and ovulations. 
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It is apparent that many studies need to be 
carried out to define specific ZP antigens which can 
effectively produce an immune response that results in 
reversible infertility or permanent sterilization. The 
advances in researchers' understanding of the devel- 
opment of the ovary, as well as the advances in 
molecular cloning techniques should allow investiga- 
tors to identity specific antigens rapidly. 
Trophoblast Antigens 
The principal precursor of the fetal placenta is the 
trophoblast, which is composed of a group of cells that 
surround the developing embryo at the blastocyst 
stage. Research to identify and characterize specific 
trophoblast antigens has been important because they 
have provided the basis for studying reproductive 
failure. The research into the structure and function of 
these antigens is important in studies on the maternal- 
fetal interactions that can be used to devise strategies 
for improving reproductive success (see review by 
Faulk and Hunt [1990]). Although the antigens of the 
trophoblast could be used as targets for immuno- 
contraception, the probability that many of antibodies 
directed against these antigens would result in abor- 
tive mechanism has made the development of this 
type of vaccine more controversial. 
Maior Goals and Hurdles in 
~o i t race~ t ive  Vaccine 
Development 
Large-Scale Production of Vaccinogens 
To date, development of protein-based contraceptive 
vaccines, particularly those using gamete antigens, 
has been hampered by the inability to purify sufficient 
quantities of protein. However, rapid advances in 
recombinant DNA technology and genetic engineering 
have now made it possible to generate sufficient 
quantities of any target protein antigen (see review by 
Chin [1990]). The development of vectors designed 
for vaccine delivery systems using virus expression 
systems to express large proteins-such as the 
vaccinia virus that has been devised for rabies vacci- 
nation of wild animals-may also prove useful. 
Optimizing Immune Enhancement for 
Development of Contraceptive Vaccines 
The successful development of contraceptive vaccines, 
like other vaccines, will ultimately depend on the 
production of an immune response which is sufficient 
to elicit antibodies which will neutralize either the 
hormone or specific gamete antigens (see review by 
Woodrow and Levine [1990]). It is therefore neces- 
sary to understand the potential problems in generat- 
ing a desired immune response using such vaccines. 
In general, antigens contain multiple regions (anti- 
genic determinants) that are capable of being recog- 
nized by an antibody. These antigenic determinants 
may be associated with almost any molecular structure 
and may be associated with the peptide backbone of a 
protein or a carbohydrate of structure conformation. 
lmmunogens have been defined as those chemical 
substances that are capable of inducing a specific 
immune response (see general discussions by 
Benaceraf and Unanue [I9791 and Berzofsky and 
Berkower [1989]). Many molecules that are antigenic 
are not always immunogenic. In general, immuno- 
genicity can often be achieved by covalently attaching 
defined molecules to a larger molecule called a 
carrier. Although many such studies have been 
carried out to study the immune response experimen- 
tally, fewer studies have been carried out to define 
specific molecules that can be effectively used in 
vaccines. 
Another critical factor in the development of 
vaccines has been the identification of molecules that 
enhance the immune response. The use of adjuvants, 
which are agents that potentiate the immune response, 
has therefore become common. The term "adjuvant" 
has been defined as an agent that augments a spe- 
cific immune response to antigens (Allison and Byars 
1990). The adjuvant most commonly used is Freund's 
complete adjuvant, which contains a bacteria suspen- 
sion in an oil vehicle. When it is inoculated with other 
specific antigens, this adjuvant induces a heightened 
immune response. Although Freund's is useful as an 
enhancing agent, it may also cause a variety of 
adverse reactions and is therefore not generally 
acceptable for use in clinical trials. 
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Recent studies using highly purified antigens 
alone have demonstrated the need for adequate 
adjuvants that can be used to enhance the immuno- 
genicity molecules that are to be used in vaccines. In 
response, a variety of adjuvants have been introduced 
(see reviews by Allison and Byars [1990], Anderson 
and Capetola [1990], and Alam et al. [1991]), but their 
efficacy has yet to be proven in extensive clinical 
trials. It is apparent that, until such immune enhance- 
ment agents are readily available, many of the immuno- 
gens targeted for contraceptive vaccines cannot 
effectively be evaluated. The advances being made in 
other areas of vaccine development will therefore be 
critical for the future development of effective contra- 
ceptive vaccines. 
Strateav for Develo~ment of 
contraceptive vaccines for 
Wildlife Populations 
Based on observations that all nonrodent mammalian 
species tested to date have multiple ZP proteins which 
share antigenic determinants with other mammalian 
species, it is likely that the ZP proteins of elephant ZP 
will also contain similar antigenic determinants. It is 
possible to identify such antigens using as few as 
20-30 zonae pellucidae using immunoblot analysis of 
ZP glycoproteins separated by one- and two-dimensional 
poiyacrylamide gel electrophoresis. In this manner, it 
is possible to rapidly identify candidate ZP antigens. 
These procedures have been successful for identifica- 
tion of horse and deer antigens. Specific polyclonal 
as well as monoclonal antibodies are now available to 
ZP proteins of numerous mammalian species, and 
analyses can easily be used to define specific ZP 
antigens of the zonae pellucidae of different wildlife 
species. Furthermore, it has been possible to use 
cDNA's from the rabbit (Schwoebel et al. 1991) to 
isolate a cDNA from the pig's zonae pellucidae and to 
use mice ZP cDNA's to isolate human cDNA's 
(Chamberlain and Dean 1990, Liang and Dean 1993). 
Despite the availability of cDNA sequences for 
ZP proteins of numerous species, it will ultimately be 
necessary to express sufficient quantities of proteins 
to use in fertility studies in target animal species. 
Initially, it will be essential to determine if immunization 
of individual species with ZP proteins will elicit a 
humoral immune response resulting in the production 
of antibodies to self ZP antigens. Secondly, it will be 
important to establish the stage of ovarian develop- 
ment during which the zonae pellucidae are formed, 
as well as the time of transition of oocyte recruitment 
from meiotic prophase to the time of ovulation. This 
timeframe is estimated to be 2 weeks in mice and up 
to 6 months in humans (Gougeon 1982). Because the 
time of exposure of oocytes in the developing follicle 
to antibodies is critical, it is important to understand 
the basic development of the ovary in each mammalian 
species for which contraceptive vaccines are being 
evaluated. The stage-specific expression of ZP 
proteins during ovarian development can easily be 
carried out using established immunocytochemistry 
methods or in situ hybridization methods. Once these 
studies are carried out for a target species, it should 
be possible to rapidly evaluate the potential for 
efficacy, safety, and reversibility of immunocontraception 
using these procedures. In some instances, small 
numbers of animals (e.g., elephants and some zoo 
animals) will need to be vaccinated for contraception 
or sterilization as compared to other large animal or 
human populations. It may be necessary, however, to 
identify the "species-specific" ZP antigenic domains for 
different target animals. Although this identification 
could pose a significant challenge, such species- 
specific vaccines will be essential if large-scale oral 
vaccine delivery systems are to be utilized. 
Considerations for the 
Development of Vaccines for 
Wildlife Management 
In order to design an effective contraceptive or steril- 
ization vaccine for any wildlife species, it is necessary 
to take into consideration the long-term effects on the 
animal populations. For example, it may be desirable 
to develop methods for large-scale sterilization in 
animal species that are clearly not in danger of 
becoming extinct but whose population has become 
so excessive that starvation or other ~roblems arise. 
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If extinction or reduction of the gene pool is, in fact, a 
consideration in an animal species, it will be important 
to consider contraception rather than sterilization. 
Because the zonae pellucidae are composed of 
distinct antigens that occur at different stages in 
oocyte growth and ovarian follicular development, they 
provide target antigens that can be developed to 
cause permanent sterilization instead of temporary 
contraception. However, the dissection of these 
antigenic domains can be carried out only by using 
advanced techniques such as recombinant DNA or 
peptide chemistry. 
The efficacy of these methods is dependent 
upon the development of the ovary and the nature of 
the ovarian cycle, and it is important to develop a 
better understanding of the reproductive cycles of the 
females of any animal. 
Summary 
Development of most of the contraceptive vaccines, 
particularly those using gamete antigens, has been 
hampered by the inability to purify sufficient quantities 
of protein for development and use. The rapid ad- 
vances in recombinant DNA technology and genetic 
engineering have now made it possible to generate 
sufficient quantities of any target protein antigen that 
has been identified. The use of these techniques for 
development of vaccines will ultimately depend on the 
production of an immune response sufficient to elicit 
antibodies that will neutralize either the hormones or 
the specific gamete antigens. This aspect of vaccine 
development is greatly dependent upon the production 
of more effective and safe adjuvant. 
Although the "ideal" vaccine has yet to be 
formulated, research in this area has provided a great 
deal of information relating to the fundamental mecha- 
nisms of hormone action, gamete interaction, fertiliza- 
tion, and implantation. These detailed studies have 
been important not only in laying the foundation for the 
future development of contraceptive and sterilization 
methods but also in developing a better understanding 
of reproductive systems that may in turn shed light on 
reproductive dysfunction, disease, and infertility. 
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